MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute fo	r form 1449E	3/PTO		Complete if Known
	INFORMATIO	ON DISCLO	DSURE	Application Number	Unassigned 10/773,39%
	STATEMENT	T BY APPL	ICANT	Filing Date	02/09/2004
	Date Submitte	d: Februari	9 2004	First Named Inventor	Andrew Cook et al.
Date Submitted: February 9, 2004				Group Art Unit	Unassigned 164
	(use as many s	heets as n	ecessary)	Examiner Name	Unassigned L. Cook
Sheet	1	of	5	Attorney Docket Number	017227-0197

	U.S. PATENT DOCUMENTS							
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,		
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
	A1							
	A2							

				F	OREIGN PAT	ENT DOCUMENT	rs		
Evenines		Foreign Patent Document			Nome of	Setentes er	Date of Publication of Cited Document	Pages, Columns, Lines,	
	Cite No. <sup>1</sup>	Office	Number <sup>4</sup>	Kind Code <sup>5</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Documents	MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
LYC	B1	JP	62-12800	Α	JAPAN	0	01/21/1987		J
	B2								
	B3								
	B4								
	B5								

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Te
WCI	C1	Andersson, M. A., et al., "Analysis of Type II Collagen Reactive T Cells in the Mouse" Scand. J. Immunol, Vol. 33, pp. 505-510 (1991)	
	C2	Miyahara, H., et al., "Identification and Characterization of a Major Tolerogenic T-cell Epitope of Type II Collagen that Suppresses Arthritis in B10.RIII Mice", Immunology, Vol. 86, pp. 110-115 (1995)	
	C3	Nabozny, G.H., et al., "Identification of a Cyanogen Bromide Fragment of Porcine Type II Collagen Capable of Modulating Collagen Arthritis in B10.RIII (H2 <sup>1)</sup> Mice <sup>1</sup> Autoimmunity Vol 20, pp. 39-49	
	C4	Kerwar, S.S., et al., "Type II Collagen Induced Arthritis in Rats: Clinical and Immunological Studies", Int. J. Tiss. Reac. Vol. VII(6), pp. 409-429	
	C5	Rowley, M.J., et al., "Epitope Specificty of Antibodies to Type II Collegan in Rheumatoid Arthritis and Systemic Lupu Erythematosus", Rheumatology International, Vol. 12(2), pp. 65-69.	
LYC	C6	Boissier, M.C., et al., "Role De La Conformation Du Collagene Dans L'Immunite Anti-Collagene De Type II Au Cours De La Polyarthrite Rhumatoide", Revue du Rhumatisme, Vol. 58(1), pp. 19-24 (1991)	
	C7		
	C8		

1) only abstrach considered (english) LYCOOK 8/17/05

Examiner Signature	Risa. X	Cod	Date Considered	8/17/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents, <sup>3</sup>Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Page 2 of 5

Form PTO-144	9	U.S. DEPARTMEN	IT OF COMMERCE	ATTY. DOCKET NO.		SERIAL NO.			
(MODIFIED)		PATENT AND TRA	ADEMARK OFFICE	017227/0	197	Unassigned			
			0.747.04.	APPLICANT					
INFO	RMATIC	ON DISCLOSURE	CHATION	Andrew COOK et al.					
				FILING DATE GROUP ART				1	
	(Use se	veral sheets if neces	<del> </del>	02/09/20	004	Una	ssigned		
			U.S. PATEN	T DOCUMENTS				· · ·	
EXAMINER	DOCUMENT DATE		DATE	NAME	CLASS	SUB-	FILING		
INITIAL	REF	NUMBER	DATE	TANIAIC	02.00	CLASS	APPRO		
						+			
						<u> </u>	l		
			FOREIGN PAT	ENT DOCUMENTS		<del>.,</del>	T-04110	47/01	
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS	NO	
	<u> </u>	NOMBER				1	163	NO	
						<u> </u>			
					<u> </u>				
		_							
			·	uthor, Title, Date, Pe					
WCI		Bornstein, P. and S	Sage, H. (1980). Struc	turally distinct collagen	Types. Ann. Re	v. Biochem.	19:957-100	)3.	
		Brodsky, B. and Sh	ah, N.K. (1995). The	triple-helix motif in prote	eins FASEB J. 9	9:1537-1546 			
			16 A	s, I., Clague, R.B., Holt,	D 11 (1000) 1	Divorcity of as	tihodies to	hene II	
		collagen in patients	with rheumatoid arth	ritis: detection by bindir	ng to –chains ar	nd to cyanoge	n bromide	type ii	
		peptides. Brit. J. RI	neumatol. 29:254-258					<del></del>	
		Charriere, G., Harti II, IX, and XI collag	mann, D.J., Vignon, E en in the serum of pa	., Ronziere, M-C., Herb tients with rheumatic di	age D., Ville, G seases. Arthritis	. (1988). Antil Rheum. 31:	oodies to t 325-332.	ypes I,	
ļ	ļ	05: 51/2 0	h D.A. 14-031 4114	/ Betomen 15 Cala	MG Vark 15	2 /1089\ A4	oantihodio	e to	
		type II collagen: oc	currence in rheumato	/., Bateman, J.F., Cole, id arthritis, other arthriti Rheum. Dis. 47:313-322	ides, autoimmui	ne connective	diseases,	and	
,		Clague, R.B., Shav	v, M.J., Holt, P.J.L. (1	980). Incidence of seru	m antibodies to	native type I	and type II		
LYC		collagen in patients	s with inflammatory ar	thritis . Ann. Rheum. Di	is. 39:201-206.				
EXAMINER	DATE	CONSIDERED	Aisa. Llon	<del>/</del>	8/17/05				
•	EXAN	IINER: Initial if ci	tation considered	, whether or not cit	ation is in co	nformance	with MP	EP 609;	
		line through citat next communication		ormance and not co	iisiaerea. Inc	nuue any C	opy or th	iis iorm	

Page 3 of 5

			<del>,                                     </del>	ragesors			
Form PTO-14	149	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.			
(MODIFIED)		PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned			
			APPLICANT	_			
INFO	DRMATI	ON DISCLOSURE CITATION	Andrew COOK et al.				
			FILING DATE	GROUP ART UNIT			
	(Use se	everal sheets if necessary)	02/09/2004	Unassigned			
		OTHER DOCUMENTS (Including A					
LVCI		Collier, D.H., Kerwar, S.S., Garovoy, M.R response gene products in rheumatoid at					
		Cook, A.D., Rowley, M.J., Stockman, A., collagen in early rheumatoid arthritis. J. F		ecificity of antibodies of type II			
Ì							
		Cook, A.D., Rowley, M.J., Mackay, I.R., Crheumatoid arthritis: correlation with disease					
		Courtenay, J.S., Dallman, M.J., Dayan, A heterologous type II collagen induces art		nmunization against			
		Fujii, K., Tsuji, M., Kitamura, A., Murota, l assay in rheumatoid arthritis. Int. Orthop.		of anti-type II collagen antibody			
			,				
		Gay, S., Gay R.E. and Miller, E.J. (1980)	The collagens of the joint. Arthritis Rh	eum. 23:937-941.			
		Gioud, M., Meghlaoui, A., Costa, O., Mor by an enzyme linked immunosorbent ass Collagen Rel. Res. 2:557-564.					
		Heinegard, D. and Paulsson, M. (1987).	Methods Enzymol. 145:336-363.				
		•		•			
		Hochberg, M.C. (1981). Adult and Juveni Rev. 3:27-44.	le rheumatoid arthritis: current epidem	ologic concepts. Epidemiol.			
			•				
		Miller, E.J. (1985). The structure of fibril-1	orming collagens. Ann. N.Y. Acad. Sci	. 460:1-13.			
			·				
		Miller, E.J. and Lunde, L.G. (1973). Isola alpha-I(II) chain of bovine and human car					
		Miller, E.J. and Rhodes, R.K. (1982). Pre Enzymol. 82:33-64.	paration and characterization of the dif	ferent types of collagen. Meth.			
		Morgan, K., Clague, R.B., Collins, I., Aya native and denature cartilage collagens (Rheum. Dis. 46:902-907.	d, S., Phinn, S.D., Holt, P.J.L. (1987). I types II, IX, and XI) and to type I collag	ncidence of antibodies to en in rheumatoid arthritis. Ann.			
LYC		Morgan, K., Clague, R.B., Collins, I., Aya anticollagen antibodies in patients with rh					

				Page 4 of	
orm PTO-14	149	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.	
MODIFIED)		PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned	
INE	SEMATI	ON DISCLOSURE CITATION	APPLICANT Andrew COOK et al.		
1141 \		ON DIOCEOUNE ON A HON	FILING DATE	GROUP ART UNIT	
	()	everal sheets if necessary)	02/09/2004	Unassigned	
<del></del>	(038.3	OTHER DOCUMENTS (Including A	l	<u></u>	
	<del></del>	Pereira, R.S., Black, C.M., Duance, V.C.,	lones V.E. Jacoby R.K. Welsh	K I (1985) Disappearing collage	
VC,		antibodies in rheumatoid arthritis. Lancet		, Kii. (1000) Disappearing consign	
		Piez, K.A. (1976). Primary structure. In B Plenum, New York, pp 1-44.	iochemistry of collagen. Ramchar	ndran, G.H. and Reddi, A.N. (eds).	
		Piez, K.A. (1982). Structure and assemble	y of the native collagen fibril. Con	nect Tissue Res. 10:25-36.	
		Rosenberg, A.M., Hunt, D.W.C., Pretty, F children with rheumatic diseases. J. Rhe		nd denatured type II collagen in	
		Rowley, M.J., Gershwin, M.E., Mackay, I. rheumatoid arthritis: differences in levels	R. (1988). Collagen antibodies in and type-specificity. J. Rheumato	juvenile arthritis and adult I. 15:289-294.	
		Rowley, M.J., Mackay, I.R., Brand, C.A., type II collagen in rheumatoid arthritis an	Bateman, J.F., Chan, D. (1992). I d systemic lupus erythematosus.	Epitope specificity of antibodies of Rheumatol. Int. 12:65-69	
		Scott, P.G. and Veis, A. (1976) The cyan Connect Tissue Res. 4:107-116.	ogen bromide peotides of bovine	soluble and insoluble collagens.	
		Stuart, J.M., Huffstutter, E.H., Townes, A I, II, III, IV and V collagen in rheumatoid radioimmunoassay. Arthritis Rheum. 26:	arthritis and other rheumatic disea	and specificity of antibodies to typ ases as measured by 125 I-	
		Steffen, C., Timpl R. (1963). Antigenicity rheumatoid arthritis sera. Int. Arch. Allerg		the serological investigation of	
			1 1		
		Stockman, A., Rowley, M.J., Emery, P., I collagen antibodies: a prospective study	Muirden, K.D. (1989). Activity of rh . Rheumatol. Int. 8:239-243	neumatoid arthritis and levels of	
		Terato, K. Cremer, M.A., Hasty, K.A., Ka immunological studies of the renatured a collagen. Coll. Rel. Res. 5:469-480.	ng, A.H., Hasty, D.L., Townes, A. alpha I(II) chains and isolated cyar	S. (1985). Physicochemical and nogen bromide peptides of type II	
		Terato, K., Shimozuru, Y., Katayama, K. Kobayashi, S., Goto, M., Nishioka, K., M collagen in rheumatoid arthritis. Arthritis	iyatsaka, N., Nagai, Y. (1990). Sp	ratsu, M., Fujii, K., Sagara, M., ecificity of antibodies of type II	
- 1	ļ		I. (1977). Autoimmunity to type II (		

			Page 5 of 5
Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	017227/0197	Unassigned
		APPLICANT	
INFORM	ATION DISCLOSURE CITATION	Andrew	COOK et al.
		FILING DATE	GROUP ART UNIT
(U:	se several sheets if necessary)	02/09/2004	Unassigned
WC	of psoriatic and rheumatoid arthritis. Arth	ritis Rheum. 24:1363-1369.	
. 10	Trentham, D.E. Kammer, G.M., McCune,	W.J., David, J.R. (1981). Autoim	munity to collagen. A shared feature
<u> </u>	or psonatic and medinatold artifitis. Artif	inus Kneum. 24.1303-1309.	
WC	Werkmeister, J.A., Ramshaw, J.A. M (19 274:895-898.	91). Multiple antigenic determina	nts on type III collagen. Biochem J.
1			